Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 28 adult patients with unresectable, disseminated gastrointestinal cancer FU pharmacokinetics as well as hematological and gastrointestinal side-effects of the therapy were evaluated to determine it they were circadian-stage dependent. FU was given as a bolus i.v. injection (15 mg/kg) 4 times at 0100, 0700, 1300, and 1900 at intervals of at least 96h in a changing sequence. Pharmacokinetic parameters were calculated on the basis of drug concentration in the serum, measured by the gas-chromatography method. Hematological side-effects were evaluated on the basis of white blood cell and thrombocyte count. Gastrointestinal toxicity (nausea, vomiting and diarrhoea graded in own 0-2 scale) was evaluated after the therapy. The single-cosinor analysis was applied for both detection and characterization of circadian rhythms. The results of the study were as follows: 1. Pharmacokinetic parameters of FU depend on the time of injection with the highest drug biotransformation at midday and early afternoon. 2. The highest white blood cell count following FU administration was noted after the night injection (0100), though the time of administration did not affect thrombocyte count and gastrointestinal side-effects.
 ...
PMID:Circadian rhythm of 5-fluorouracil (FU) pharmacokinetics and tolerance. 235 Sep 85

A phase II study on THP((2''R)-4'-0-Tetrahydropyranyladriamycin) was performed in 47 patients with advanced or recurrent gastrointestinal cancer through the cooperation of nine institutions in Hiroshima Prefecture from April 1982 to November 1984. THP was given by means of intravenous infusion and/or intraaortic infusion and the 47 cases were divided into two groups according to the method of administration: (A) 40-60 mg/body every 3 or 4 weeks, or (B) 30 mg/body every week. Among 24 evaluable cases, partial response (PR) was observed in two cases of recurrent metastatic lymph nodes in gastric cancer patients. The (A) method of administration was more effective than (B). Subjective side effects observed were appetite loss, nausea, vomiting and general fatigue, but these were not so severe. Leukocyte nadir occurred at the 1st or 2nd week of THP administration, but thrombocytes were not appreciably decreased.
 ...
PMID:[Phase II study of THP patients with gastrointestinal cancer]. 394 11

A phase II study on MCNU (Methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside) was performed in 33 patients with advanced or recurrent gastrointestinal cancer under the cooperation of eight institutions in Hiroshima Prefecture. MCNU was given by means of intravenous drip infusion and the 33 cases were divided into three groups according to the method of administration; (A) 50mg/m2 every 1 or 2 weeks, (B) 70mg/m2 every 2 weeks or (C) 90mg/m2 every 6-8 weeks. Among 28 evaluable cases, 1 complete response (CR) and 1 partial response (PR) were observed and these two cases were gastric cancer patients. Platelet nadir occurred at the 3rd or fifth week after MCNU administration, but the leukocyte count was not so decreased. Subjective side effects were nausea, general fatigue and vomiting, but these were observed to be only mild.
 ...
PMID:[Phase II study on MCNU in patients with advanced or recurrent gastrointestinal cancer]. 403 10

The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery. The levels of 5-FU in the cancerous tissue of the stomach and the regional lymph nodes were higher in the cases who received 5-FU and ANG-II than in the cases received 5-FU alone. Based on this result, we carried out cancer chemotherapy combined with ANG-II for 15 patients with advanced cancer. The good clinical response was observed in 4 out of 15 cases (26.7%) including 2 complete (CR) and 2 partial responses (PR), respectively. According to Karnofsky's criteria of response, more than I-A response was observed in 5 out of 15 cases (33.3%). The major side effects of ANG-II therapy were nausea, vomiting and breast pain. The incidence of the side effects was 8.7% in total.
 ...
PMID:[Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)]. 682 Sep 24

During the period of January 1, 1957 to January 1, 1982, complete inpatient and outpatient records of 62 cases of synchronous cancers of the gastrointestinal tract were submitted for a retrospective analysis. The total number of gastrointestinal cancer cases from the Saint Francis General Hospital and two affiliating hospitals was 1,550 with a resultant synchronous cancer incidence of 4 percent. In this small series of 62 cases, the operability rate was 100 percent, with a resectability rate of 96 percent. The surgical morbidity and mortality rates were 12 percent and 3.2 percent, respectively.The most frequent clinical manifestations were pain, borborygmi, nausea, vomiting, food intolerance, dysphagia, hematemesis, rectal bleeding, and weight loss.The five and ten year survival in the synchronous group was 82 percent and 64 percent, respectively, as compared with 36.1 percent and 27.8 percent for the single malignant group.
 ...
PMID:Synchronous cancers of the gastrointestinal tract: results, diagnosis, and treatment. 685 66

In this study we compared 293 patients with cancer pain undergoing treatment in the years 1987 until 1993. 165 patients (55.7%) suffering from cancer localized at the organs of gastrointestinal tract. Comparing the therapeutic results of WHO pattern with patients after implantation of port systems with epidural or intrathecal catheters and portable external morphine pumps we found at port-patients a significant lower number of side effects like nausea, vomiting, obstipation and weariness. Furthermore we noted at port-patients lower values of pain score (VAS). We think the high incidence of uncomfortable side effects of drugs at patients with gastrointestinal cancer may be caused by the type of special illness. Therefore we discuss the possibility of an earlier use of the method of port implantation at special indications.
 ...
PMID:[Pain therapy of tumor patients with special reference to tumors of the gastrointestinal tract. WHO staged schedule versus para-spinal analgesia techniques]. 752 43

This study investigated, in a convenience sample of 279 patients with cancer, the trajectories of symptoms and loss of physical functioning over time, the relationships of these variables to age and co-morbidity, and differences existing according to cancer site (breast, lung, colorectal/gastrointestinal, urinary/reproductive, lymphoma, and "other"). The patients were surveyed twice; at intake (wave I, n = 279) and 6 months later (wave II, n = 160). Findings indicated, at wave I, that age and co-morbidity were significantly correlated, and loss of physical functioning was associated primarily with symptoms and, to a lesser degree, with age. Loss of function scores varied significantly according to cancer site, with higher levels for patients with lung cancer and lower levels for patients with breast or colorectal/gastrointestinal cancer. The most frequently occurring symptoms were fatigue, insomnia, pain, and nausea. Average levels of symptoms and loss of physical functioning were lower at wave II, indicative of a possible treatment-related effect (at wave II, a smaller percentage of patients had recently undergone treatment). Although co-morbidity was only modestly correlated with symptoms and loss of function for the total sample, it was highly correlated with both symptoms and loss of physical functioning for the younger patients (those younger than 60 years of age). The significant link that was identified between symptoms and loss of physical functioning has important implications for physicians, nurses, and other healthcare providers caring for patients with cancer as they deal with symptom management and quality-of-life issues.
 ...
PMID:Loss of physical functioning among patients with cancer: a longitudinal view. 811 37

Combination chemotherapy of Furtulon/low-dose cisplatin (CDDP) was administered to 13 patients with unresectable advanced gastrointestinal carcinoma (including 4 cases of gastric cancer, 6 of colorectal cancer, 1 of pancreatic cancer, 1 of hepatic cancer, and 1 of esophageal cancer). All patients were unresectable due to poor performance status (PS > 3) or metastasis. They were treated with Furtulon 1,200 mg/day orally on days 1-10 followed by 4 drug-free days, every 2 weeks, and CDDP 3.5 mg/m2/day, on days 1-5 by i.v. followed by 2 drug-free days every 4 weeks repeatedly. An average of 2-3 cycles were used. Six out of 13 patients had a partial response, 5 had no change, and 2 had progressive disease. The response rate was 46% and median survival time was 320 days. After chemotherapy, there was an increase in appetite and body weight in 11 patients (85%), and the patients maintained a good performance status and quality of life. Moreover no renal dysfunction occurred after treatment with CDDP. There was no high-grade toxicity over grade 2, only slight nausea, vomiting and diarrhea. From the present study, combination chemotherapy of Furtulon/low-dose CDDP seems to be effective for patients with advanced gastrointestinal cancer, and to have improved their quality of life (QOL).
 ...
PMID:[Clinical evaluation of effects and improvement in quality of life from palliative therapy of combination chemotherapy with Furtulon and consecutive low-dose cisplatin in cases of unresectable advanced gastrointestinal carcinoma]. 1124 47

Anthracyclines, together with taxanes, are at present the most active agents in metastatic breast cancer, while single-agent, bolus 5-fluorouracil (5-FU) is not very active in this setting. In view of encouraging results and tolerable toxicity of continuous infusion of 5-FU in gastrointestinal cancer, innovative oral 5-FU agents such as capecitabine have been developed. Capecitabine is a prodrug that is converted into the active compound 5-FU preferentially at the tumor site. An intermittent dosing schedule of capecitabine twice daily at a dose of 2510 mg/m2/day on days 1-14 in a 3-week cycle appeared to be feasible and resulted in a high dose intensity. A large phase II study investigating capecitabine in 135 advanced breast cancer patients, pretreated with anthracyclines and taxanes, observed three complete and 24 partial responses (response rate, 20%), with a mean duration of 8.0 months. Preliminary results of a study comparing capecitabine with paclitaxel in 42 breast cancer patients failing anthracyclines indicate that the efficacy of capecitabine is comparable to that of paclitaxel, with response rates of 36% and 21%, respectively. Another study reported a response rate of 25% for capecitabine as first-line therapy for advanced breast cancer in women aged > or = 55 years, which tended to be better than combination chemotherapy with cyclophosphamide/methotrexate/5-FU. In all studies, capecitabine side effects were mainly mild, and treatment-related grade 3/4 toxicity consisted of diarrhea (8%-11%), nausea (4%-11%), hand-foot syndrome (10%-18%), neutropenia (3%-20%), and bilirubin elevation (6%). Capecitabine is clearly an active agent for the treatment of breast cancer. It is currently registered in various countries for use in third-line treatment of metastatic disease. Its further role will have to be defined from data of randomized phase III studies.
 ...
PMID:Capecitabine in breast cancer: current status. 1189 51

We investigated a possible relationship between levels of endogenous cortisol and severity of different symptoms in patients with advanced cancer. Twenty-three patients with predominantly gastrointestinal cancer, recruited in a palliative care unit, entered the study. Urinary free cortisol (UFC) was measured together with demographic data, blood parameters, tumour burden, concurrent illness, medication, nutritional status and quality of life. Significant positive correlations were found between levels of endogenous cortisol and appetite loss, fatigue and nausea/vomiting. The findings support the view of a chronic stress condition in advanced cancer. Interaction between cytokines and the hypothalamic-pituitary-adrenal (HPA) axis may also be important in the interpretation of the results.
 ...
PMID:Symptoms in advanced cancer: relationship to endogenous cortisol levels. 1452 83


1 2 Next >>